A federal judge in Louisiana has scheduled an initial court hearing for a batch of lawsuits that claim Takeda Pharmaceuticals’ top-selling diabetes drug, Actos, carries an increased risk of bladder cancer.

This observational, cohort study was conducted in patients with T2DM and SHF attending an Australian tertiary teaching hospital’s heart failure services. The primary endpoint was glycaemic control measured by glycosylated haemoglobin (HbA1c) at initiation and top dose of BB.

BYDUREON is an injectable prescription medicine that may improve blood sugar in adults with type 2 diabetes mellitus, and should be used along with diet and exercise.

Feb 9th 2012. The FDA said that more data is needed because of safety concerns linking dapagliflozin with breast cancer and bladder cancer. An FDA review of the data found a fourfold increased risk for breast cancer and fivefold increased risk for bladder cancer with dapagliflozin.

Feb 7th 2011. A new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA® (sitagliptin), with extended-release metformin has been approved by the FDA.  The combination of both active substances provides greater A1C goal attainment compared to sitagliptin or metformin alone